Get the free Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein - dtic

This document presents an annual evaluation report on the efficacy of molecular inhibitors targeting the c-Myc oncoprotein, focusing on research methods, findings, and future directions in cancer

How to fill out evaluation of molecular inhibitors

How to fill out Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein

1. Gather all necessary research materials and relevant data on c-Myc oncoprotein.
2. Identify the specific molecular inhibitors to be evaluated.
3. Establish the criteria for evaluation including effectiveness, selectivity, and safety.
4. Design experiments to test the inhibitors against c-Myc.
5. Collect and analyze data from the experiments.
6. Document the findings systematically.
7. Write a detailed report summarizing the methodology, results, and conclusions.

Who needs Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

1. Researchers working in cancer biology and oncology.
2. Pharmaceutical companies developing targeted cancer therapies.
3. Clinical practitioners looking for innovative treatment options for patients.
4. Academic institutions conducting studies on cancer mechanisms.

People Also Ask about

What is the function of the C-MYC?

The c-Myc gene serves as a “master regulator” of cellular metabolism and proliferation. Since it is activated by a large number of oncogenic pathways and, in turn, stimulates many of the metabolic changes that result in malignant transformation, it is truly “both the chicken and the egg”.

What does MYC inhibitor do?

In vivo studies show that MYC inhibition elicits a prominent anti-proliferative effect and sustained tumor regression while any alteration on healthy tissue remains reversible. This opens an exploitable window for treatment that makes MYC one of the most appealing therapeutic targets for cancer drug development.

What is the function of the MYC factor?

A well-known fundamental function of MYC is induction of apoptosis. MYC transcription factor has a dual role in tumor cells. It can activate and repress various downstream pathways that can induce proliferation or apoptosis [6].

What is the MYC gene responsible for?

MYC regulates the expression of gene products through direct activation or inhibition of gene transcription,5 transcriptional amplification,3,4,13 the induction of microRNA and chromatin regulators,14,15 and/or the global regulation of RNA and protein biogenesis.

Which disease is associated with MYC?

Abstract. The proto-oncogene Myc serves as a paradigm for understanding the dynamics of transcriptional regulation. Myc protein has been linked to immune dysfunction, cancer development and neoplastic transformation.

What is the C-myc mutation seen in?

c-myc is often rearranged in tumors resulting in deregulated expression. In addition, mutations in the coding region of c-myc are frequently found in human lymphomas, a hot spot being the Thr58 phosphorylation site, a mutation shown to enhance the transforming capacity of c-Myc.

What does the MYCN gene do?

The MYCN protein regulates the activity of other genes by attaching (binding) to specific regions of DNA and controlling the first step of protein production (transcription). On the basis of this action, this protein is called a transcription factor. The MYCN gene belongs to a class of genes known as oncogenes.

What is the function of normal MYC?

The N-terminal region will bind with co-activator complexes, making MYC acts as the transcription or repression factor (Cowling et al 2006). In normal cells, MYC is tightly regulated by mitotic and developmental signals, and in turn, it regulates the expression of downstream target genes.

What cancer is associated with MYC?

MYC is frequently translocated in multiple myeloma (Shou et al., 2000) and is one of the most highly amplified oncogene among many different human cancers (Beroukhim et al., 2010). Defects in the Wnt-APC pathway found in human colon carcinoma results in enhanced TCF transcriptional activation of MYC (He et al., 1998).

What is MYC inhibitor?

Among the 'most wanted' targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein.

For pdfFiller’s FAQs

What is Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

The Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein refers to the assessment and testing of specific compounds or drugs that can inhibit the activity or expression of the c-Myc oncoprotein, which is implicated in various cancers.

Who is required to file Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

Researchers, pharmaceutical companies, and clinical trial sponsors who are involved in the development and testing of drugs targeting the c-Myc oncoprotein are typically required to file the evaluation.

How to fill out Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

To fill out the evaluation, one should provide comprehensive data on the molecular inhibitors studied, including their chemical structure, biological activity, experimental methods used, results, and conclusions drawn from the research.

What is the purpose of Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

The purpose of the evaluation is to determine the effectiveness and safety of molecular inhibitors against the c-Myc oncoprotein, which could lead to new therapeutic options for cancers associated with c-Myc dysregulation.

What information must be reported on Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein?

The information that must be reported includes the rationale for the study, the methodology employed, the results obtained, any side effects observed, and overall conclusions regarding the inhibitors' potential for clinical use.